BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhuang C, Wang P, Sun T, Zheng L, Ming L. Expression levels and prognostic values of annexins in liver cancer. Oncol Lett. 2019;18:6657-6669. [PMID: 31807177 DOI: 10.3892/ol.2019.11025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Qiu LW, Liu YF, Cao XQ, Wang Y, Cui XH, Ye X, Huang SW, Xie HJ, Zhang HJ. Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment. World J Gastroenterol 2020; 26(18): 2126-2137 [PMID: 32476780 DOI: 10.3748/wjg.v26.i18.2126] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
2 Guo J, Fang Q, Liu Y, Xie W, Zhang Y, Li C. Identifying critical protein-coding genes and long non-coding RNAs in non-functioning pituitary adenoma recurrence. Oncol Lett 2021;21:264. [PMID: 33664827 DOI: 10.3892/ol.2021.12525] [Reference Citation Analysis]
3 Serag WM, Elsayed BE. Annexin A5 as a marker for hepatocellular carcinoma in cirrhotic hepatitis C virus patients. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00101-y] [Reference Citation Analysis]
4 Liu Q, Du X, Yu Z, Yao Q, Meng X, Zhang K, Zheng L, Hong W. STARD5 as a potential clinical target of hepatocellular carcinoma. Med Oncol 2022;39:156. [PMID: 35852638 DOI: 10.1007/s12032-022-01750-8] [Reference Citation Analysis]
5 Shao YY, Kuo HY, Jeng YM, Wu YM, Wang HP, Hsu C, Hsu CH, Hsu HC, Cheng AL, Lin ZZ. Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma. BMC Cancer 2022;22:219. [PMID: 35227227 DOI: 10.1186/s12885-022-09288-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhao J, Chang L, Tu J, Sun B, Wei X, Anand V. Evaluation of Annexins Family as Potential Biomarker for Predicting Progression and Prognosis in Clear Renal Cell Carcinoma. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-13. [DOI: 10.1155/2022/8748434] [Reference Citation Analysis]
7 Gao S, Wang Z, Liu X, Xu B, Liu F. The calcimedin annexin A3 displays tumor-promoting effect in esophageal squamous cell carcinoma by activating NF-κB signaling. Mamm Genome 2021. [PMID: 34109455 DOI: 10.1007/s00335-021-09883-3] [Reference Citation Analysis]
8 Ouyang G, Yi B, Pan G, Chen X. A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma. Cancer Cell Int 2020;20:207. [PMID: 32514252 DOI: 10.1186/s12935-020-01294-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
9 Xu J, Liu D, Liu Z, Yang J, Chen H. Mechanism of a Herbal Formula Associated with Prognosis and Immune Infiltration in LIHC: Transcriptomics Analysis and Molecular Dynamics Simulations. Evid Based Complement Alternat Med 2022;2022:6084321. [PMID: 35754689 DOI: 10.1155/2022/6084321] [Reference Citation Analysis]
10 Serag WM, Mohammed BSE, Mohamed MM, Elsayed BE. Predicting the risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. Heliyon 2020;6:e04677. [PMID: 32904199 DOI: 10.1016/j.heliyon.2020.e04677] [Reference Citation Analysis]